Nuvalent, Inc. NUVL
We take great care to ensure that the data presented and summarized in this overview for Nuvalent, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NUVL
View all-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.4 Billion32.3% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$411 Million19.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.44MShares$346 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$236 Million0.01% of portfolio
-
Commodore Capital LP New York, NY1.86MShares$145 Million12.88% of portfolio
-
Perceptive Advisors LLC New York, NY1.63MShares$127 Million4.85% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.45MShares$113 Million0.01% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA1.45MShares$113 Million34.45% of portfolio
-
Wellington Management Group LLP Boston, MA1.44MShares$112 Million0.02% of portfolio
-
State Street Corp Boston, MA1.43MShares$111 Million0.0% of portfolio
Latest Institutional Activity in NUVL
Top Purchases
Top Sells
About NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at NUVL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 16
2025
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,700
-19.23%
|
$1,249,500
$85.1 P/Share
|
|
Jul 16
2025
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,700
+16.13%
|
$264,600
$18.93 P/Share
|
|
Jul 15
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-2.5%
|
$2,241,000
$83.11 P/Share
|
|
Jul 15
2025
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+8.91%
|
$486,000
$18.93 P/Share
|
|
Jul 15
2025
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,300
-2.03%
|
$445,200
$84.23 P/Share
|
|
Jul 15
2025
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+7.33%
|
$95,400
$18.93 P/Share
|
|
Jul 10
2025
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,500
-4.15%
|
$440,000
$80.43 P/Share
|
|
Jul 10
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+2.65%
|
$137,500
$25.37 P/Share
|
|
Jul 09
2025
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,145
-1.7%
|
$173,745
$81.49 P/Share
|
|
Jun 27
2025
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-24.47%
|
$1,600,000
$80.02 P/Share
|
|
Jun 27
2025
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+19.66%
|
$360,000
$18.93 P/Share
|
|
Jun 27
2025
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,170
-3.32%
|
$171,430
$79.92 P/Share
|
|
Jun 27
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,170
+1.63%
|
$60,760
$28.59 P/Share
|
|
Jun 26
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,000
-2.58%
|
$312,000
$78.41 P/Share
|
|
Jun 26
2025
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+7.14%
|
$108,000
$27.85 P/Share
|
|
Jun 25
2025
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,630
-12.03%
|
$681,770
$79.87 P/Share
|
|
Jun 25
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,630
+5.84%
|
$241,640
$28.59 P/Share
|
|
Jun 18
2025
|
James E Flynn Director |
BUY
Grant, award, or other acquisition
|
Indirect |
5,294
+50.0%
|
-
|
|
Jun 18
2025
|
Cameron Wheeler |
BUY
Grant, award, or other acquisition
|
Direct |
2,647
+33.97%
|
-
|
|
Jun 18
2025
|
Michael L. Meyers |
BUY
Grant, award, or other acquisition
|
Direct |
2,647
+33.97%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 181K shares |
|---|---|
| Exercise of conversion of derivative security | 524K shares |
| Open market or private sale | 3.82M shares |
|---|